Séverine Vermeire Selected Research

Crohn Disease (Crohn's Disease)

6/2022	Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib.
5/2022	Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study.
1/2022	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
1/2022	Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials.
1/2022	Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.
1/2022	Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease.
1/2022	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study.
1/2022	Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
1/2022	Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
12/2021	Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Séverine Vermeire Research Topics

Disease

107	Crohn Disease (Crohn's Disease) 06/2022 - 05/2004
96	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 09/2004
89	Ulcerative Colitis 11/2022 - 10/2003
33	Necrosis 01/2022 - 07/2006
27	Inflammation (Inflammations) 06/2022 - 09/2004
16	Infections 06/2022 - 01/2006
14	Colitis 10/2021 - 02/2007
12	Neoplasms (Cancer) 01/2022 - 12/2008
9	Disease Progression 01/2022 - 05/2008
8	Fistula 01/2022 - 07/2005
7	Rheumatoid Arthritis 01/2022 - 12/2007
6	Pouchitis 01/2022 - 01/2008
5	Ulcer 01/2022 - 01/2014
4	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 09/2012
4	Fibrosis (Cirrhosis) 01/2020 - 01/2013
4	Sclerosing Cholangitis 02/2012 - 04/2006
3	Autoimmune Diseases (Autoimmune Disease) 07/2022 - 07/2017
3	Herpes Zoster 06/2022 - 01/2017
3	Injection Site Reaction 01/2022 - 02/2014
3	Arthralgia (Joint Pain) 01/2022 - 09/2012
3	Ileitis 01/2021 - 06/2008
3	Pathologic Constriction (Stenosis) 02/2010 - 03/2007
2	Fatigue 05/2022 - 03/2016
2	Dysbiosis 01/2022 - 08/2014
2	Encephalitis (Encephalitis, Rasmussen) 10/2020 - 01/2009
2	Abscess 09/2018 - 09/2012
2	Progressive Multifocal Leukoencephalopathy 01/2018 - 07/2005
2	Psoriatic Arthritis 01/2018 - 09/2012

Drug/Important Bio-Agent (IBA)

72	Infliximab (Remicade)FDA Link 01/2022 - 05/2004
30	vedolizumabIBA 05/2022 - 09/2017
28	Pharmaceutical PreparationsIBA 07/2022 - 11/2011
25	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021 - 05/2004
22	Biological ProductsIBA 01/2022 - 07/2005
21	AntibodiesIBA 01/2020 - 12/2005
15	Adalimumab (Humira)FDA Link 07/2022 - 07/2005
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2005
15	Monoclonal AntibodiesIBA 06/2021 - 07/2005
12	tofacitinibIBA 06/2022 - 01/2017
11	SteroidsIBA 01/2022 - 02/2007
10	Ustekinumab (CNTO 1275)FDA Link 11/2022 - 07/2017
10	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 05/2004
10	C-Reactive ProteinIBA 12/2021 - 09/2004
9	Janus Kinase InhibitorsIBA 06/2022 - 01/2017
9	Phenobarbital (Luminal)FDA Link 01/2020 - 05/2004
8	Dextrans (Dextran)FDA Link 12/2020 - 01/2013
8	CytokinesIBA 11/2019 - 12/2005
7	Immunologic Factors (Immunomodulators)IBA 10/2021 - 02/2009
7	IntegrinsIBA 10/2020 - 07/2005
6	Tumor Necrosis Factor InhibitorsIBA 06/2022 - 01/2014
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2006
6	golimumab FDA Link 01/2020 - 05/2016
6	Immunoglobulin G (IgG)IBA 01/2020 - 07/2005
5	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 09/2008
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 04/2005
5	SodiumIBA 12/2020 - 01/2013
5	Interleukin-12 (IL 12)IBA 07/2019 - 07/2005
5	Natalizumab (Tysabri)FDA Link 01/2018 - 07/2005
5	Matrix Metalloproteinases (MMPs)IBA 01/2018 - 02/2014
5	Certolizumab Pegol FDA Link 01/2018 - 12/2007
4	EnzymesIBA 01/2021 - 07/2014
4	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2021 - 09/2004
4	Azathioprine (Imuran)FDA LinkGeneric 03/2019 - 09/2008
4	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2018 - 07/2014
3	GLPG0634IBA 06/2022 - 01/2017
3	ontamalimabIBA 06/2021 - 01/2017
3	Messenger RNA (mRNA)IBA 01/2020 - 01/2014
3	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2020 - 01/2018
3	Drinking WaterIBA 01/2020 - 01/2018
3	Interferon-gamma (Interferon, gamma)IBA 09/2019 - 07/2005
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 09/2004
3	Janus KinasesIBA 05/2018 - 01/2017
3	ImmunosorbentsIBA 05/2016 - 07/2014
3	Chemokine ReceptorsIBA 01/2013 - 04/2006
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2011 - 10/2003
3	purineIBA 12/2010 - 07/2009
3	PorinsIBA 06/2008 - 10/2007
2	Janus Kinase 1IBA 01/2022 - 01/2021
2	Oncostatin MIBA 10/2021 - 11/2019
2	etrasimodIBA 06/2021 - 01/2020
2	RNA (Ribonucleic Acid)IBA 03/2021 - 01/2021
2	LigandsIBA 12/2020 - 01/2018
2	Interleukin-10 (Interleukin 10)IBA 01/2020 - 11/2008
2	CT-P13IBA 01/2020 - 01/2019
2	Hydroxyproline (4 Hydroxyproline)IBA 01/2020 - 11/2019
2	Biosimilar PharmaceuticalsIBA 01/2020 - 01/2019
2	Interleukin-17 (Interleukin 17)IBA 11/2019 - 05/2018
2	Interleukin-13IBA 11/2019 - 09/2014
2	Butyrates (Butyrate)IBA 09/2019 - 08/2014
2	MicroRNAs (MicroRNA)IBA 07/2019 - 01/2014
2	TabletsIBA 05/2019 - 07/2013
2	Methotrexate (Mexate)FDA LinkGeneric 03/2019 - 01/2019
2	Sphingosine-1-Phosphate ReceptorsIBA 05/2018 - 01/2017
2	Peptides (Polypeptides)IBA 01/2017 - 10/2007
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2017 - 12/2005

Therapy/Procedure

97	Therapeutics 01/2022 - 05/2004
13	Biological Therapy 01/2022 - 07/2006
10	Colectomy 10/2021 - 09/2004
7	Restorative Proctocolectomy 10/2021 - 01/2008
2	Proctectomy 01/2022 - 07/2013
2	Oral Administration 01/2018 - 11/2016